📈 GLP-1 Titration Planner
Complete semaglutide or tirzepatide titration schedule with weekly doses, reconstitution instructions, U-100 draw volumes, and vial planning.
Why GLP-1 Agonists Require Titration
Semaglutide (Ozempic / Wegovy) and tirzepatide (Mounjaro / Zepbound) are GLP-1 receptor agonists that significantly slow gastric emptying. At full therapeutic doses, the resulting nausea, vomiting, and gastrointestinal discomfort is severe enough to cause most users to discontinue if they start at the maintenance dose. The FDA-approved titration schedules increase the dose monthly, allowing GI receptors to adapt gradually over 4–5 months.
This planner generates the complete schedule for your chosen compound, including exact weekly doses, how many vials you'll need at each phase, the correct BAC water amount to add for comfortable draw volumes, and the U-100 syringe unit mark per injection. Optionally enter your vial cost to see the total cost per phase.
Based on FDA-approved Ozempic / Wegovy prescribing information. 1 injection per week.
- Weeks 1–4: 0.25 mg (250 mcg) — introductory
- Weeks 5–8: 0.5 mg (500 mcg)
- Weeks 9–12: 1.0 mg (1,000 mcg)
- Weeks 13–16: 1.75 mg (1,750 mcg)
- Weeks 17+: 2.4 mg (2,400 mcg) — maintenance
GLP-1 Titration Planner
Select your compound and enter vial details to generate a complete schedule.
| Phase | Weeks | Weekly Dose | Doses in Phase | Vials Needed | Reconstitution | Draw (U-100) |
|---|
Reconstitution values target ~0.25 mL draw per injection. Vials per phase are calculated assuming each vial is fully used at that phase's dose. Actual vials needed may vary.
GLP-1 Titration — Frequently Asked Questions
Why can't I skip to the full dose immediately?
GLP-1 agonists dramatically slow gastric emptying. At full maintenance doses (2.4 mg semaglutide or 15 mg tirzepatide), the GI effects — nausea, vomiting, constipation, gastroparesis — are intense if introduced without titration. Clinical trials show that patients who follow the published titration schedule have substantially better tolerability, higher completion rates, and similar long-term efficacy to those who rush escalation. Starting at 2.4 mg semaglutide without titration typically causes severe nausea within hours.
Can I stay at a lower maintenance dose if I'm already seeing results?
Yes. The titration schedule sets the minimum progression — there is no requirement to reach the maximum dose. Significant efficacy is demonstrated at every level from 0.5 mg to 2.4 mg semaglutide weekly. Many practitioners follow the "lowest effective dose" principle: if you're achieving your goals at 1.0 mg with minimal side effects, staying there is clinically sensible and significantly reduces both cost and GI burden. Tirzepatide similarly shows strong efficacy at 5–7.5 mg, well below the 15 mg maximum.
What should I do if nausea is severe during titration?
Mild-to-moderate nausea in the first 1–2 weeks after each dose increase is expected and typically resolves as adaptation occurs. For management: inject before bed (sleep through the peak), eat smaller and blander meals, avoid high-fat foods and alcohol, stay well hydrated, and consider ginger supplements. If nausea is severe or includes vomiting, hold at the current dose for an additional 4 weeks before attempting to escalate. Never force escalation through severe GI distress.
How does tirzepatide differ from semaglutide?
Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist — it activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors simultaneously. This dual mechanism produces superior weight loss in head-to-head clinical comparisons. SURMOUNT-5 trial data showed tirzepatide users lost ~20% more body weight than semaglutide users. The titration schedule is longer (6 phases vs. 5) and the starting dose is 2.5 mg (10× higher than semaglutide's 0.25 mg starting dose). The GI side-effect profile is similar.